Carl Dambkowski Sells 1,590 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 1,590 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $30.48, for a total transaction of $48,463.20. Following the completion of the sale, the insider now directly owns 251,033 shares in the company, valued at $7,651,485.84. This represents a 0.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, February 5th, Carl Dambkowski sold 3,520 shares of Apogee Therapeutics stock. The shares were sold at an average price of $40.69, for a total transaction of $143,228.80.
• On Thursday, January 2nd, Carl Dambkowski sold 4,085 shares of Apogee Therapeutics stock. The shares were sold at an average price of $46.94, for a total transaction of $191,749.90.
• On Wednesday, December 11th, Carl Dambkowski sold 4,540 shares of Apogee Therapeutics stock. The shares were sold at an average price of $48.76, for a total transaction of $221,370.40.

Apogee Therapeutics Trading Up 2.0 %

Shares of APGE stock opened at $36.14 on Friday. Apogee Therapeutics, Inc. has a 1 year low of $29.10 and a 1 year high of $72.29. The firm’s fifty day moving average price is $38.92 and its two-hundred day moving average price is $46.91. The firm has a market capitalization of $1.63 billion, a P/E ratio of -14.93 and a beta of 2.46.

Apogee Therapeutics (NASDAQ:APGE) last issued its earnings results on Monday, March 3rd. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.25). As a group, equities research analysts forecast that Apogee Therapeutics, Inc. will post -3.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Apogee Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of APGE. Victory Capital Management Inc. raised its holdings in shares of Apogee Therapeutics by 121.6% in the 3rd quarter. Victory Capital Management Inc. now owns 346,358 shares of the company’s stock valued at $20,345,000 after purchasing an additional 190,092 shares during the period. Natixis Advisors LLC bought a new position in Apogee Therapeutics in the 3rd quarter valued at about $879,000. Jennison Associates LLC raised its holdings in Apogee Therapeutics by 2.1% in the 3rd quarter. Jennison Associates LLC now owns 312,611 shares of the company’s stock valued at $18,363,000 after acquiring an additional 6,533 shares during the period. Intech Investment Management LLC bought a new position in Apogee Therapeutics in the 3rd quarter valued at about $300,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in Apogee Therapeutics by 17.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 280,428 shares of the company’s stock valued at $16,472,000 after acquiring an additional 41,686 shares during the period. 79.04% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on APGE shares. Canaccord Genuity Group started coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating and a $89.00 price objective on the stock. Wedbush reiterated an “outperform” rating and issued a $90.00 price target on shares of Apogee Therapeutics in a research note on Monday, March 3rd. Guggenheim reiterated a “buy” rating on shares of Apogee Therapeutics in a research note on Monday, February 10th. Finally, Canaccord Genuity Group started coverage on shares of Apogee Therapeutics in a research note on Monday, November 25th. They issued a “buy” rating and a $89.00 price target on the stock. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $91.60.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.